AR121183A1 - Métodos de tratamiento de la nefritis lúpica con antagonistas de interleucina-17 (il-17) - Google Patents

Métodos de tratamiento de la nefritis lúpica con antagonistas de interleucina-17 (il-17)

Info

Publication number
AR121183A1
AR121183A1 ARP200103171A ARP200103171A AR121183A1 AR 121183 A1 AR121183 A1 AR 121183A1 AR P200103171 A ARP200103171 A AR P200103171A AR P200103171 A ARP200103171 A AR P200103171A AR 121183 A1 AR121183 A1 AR 121183A1
Authority
AR
Argentina
Prior art keywords
antagonists
lupus nephritis
interleukin
treatment methods
treatment
Prior art date
Application number
ARP200103171A
Other languages
English (en)
Inventor
Luminita Pricop
Wolfgang Hueber
Shephard Mpofu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR121183A1 publication Critical patent/AR121183A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente se refiere a métodos para el tratamiento de la Nefritis Lúpica (NL) usando antagonistas de IL-17, por ejemplo, secukinumab. Además se divulgan antagonistas de IL-17, por ejemplo, anticuerpos IL-17, como secukinumab, para el tratamiento de pacientes con NL, así como medicamentos, regímenes de dosificación, formulaciones farmacéuticas, formas de dosificación y kits para su uso en los usos y métodos divulgados.
ARP200103171A 2019-11-19 2020-11-17 Métodos de tratamiento de la nefritis lúpica con antagonistas de interleucina-17 (il-17) AR121183A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962937482P 2019-11-19 2019-11-19

Publications (1)

Publication Number Publication Date
AR121183A1 true AR121183A1 (es) 2022-04-27

Family

ID=73598917

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103171A AR121183A1 (es) 2019-11-19 2020-11-17 Métodos de tratamiento de la nefritis lúpica con antagonistas de interleucina-17 (il-17)

Country Status (11)

Country Link
US (1) US20230009657A1 (es)
EP (1) EP4061418A1 (es)
JP (1) JP2023502103A (es)
KR (1) KR20220103141A (es)
CN (1) CN114728060A (es)
AR (1) AR121183A1 (es)
AU (1) AU2020386669A1 (es)
CA (1) CA3161801A1 (es)
IL (1) IL292926A (es)
TW (1) TW202120546A (es)
WO (1) WO2021099924A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024026401A1 (en) * 2022-07-28 2024-02-01 Abbvie Inc. Methods of treating systemic lupus erythematosus
WO2024153223A1 (zh) * 2023-01-19 2024-07-25 上海华奥泰生物药业股份有限公司 一种治疗系统性红斑狼疮的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
EP3808769A1 (en) 2005-12-13 2021-04-21 Eli Lilly And Company Anti-il-17 antibodies
WO2007117749A2 (en) 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies fpr treating cancer
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
NZ591484A (en) 2008-09-29 2012-09-28 Roche Glycart Ag Antibodies against human il 17 and uses thereof
US8721620B2 (en) 2009-12-24 2014-05-13 Rani Therapeutics, Llc Swallowable drug delivery device and methods of drug delivery
HUE044038T2 (hu) 2010-11-05 2019-09-30 Novartis Ag Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CA2897682C (en) 2013-02-08 2023-03-14 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17

Also Published As

Publication number Publication date
KR20220103141A (ko) 2022-07-21
EP4061418A1 (en) 2022-09-28
CA3161801A1 (en) 2021-05-27
US20230009657A1 (en) 2023-01-12
JP2023502103A (ja) 2023-01-20
WO2021099924A1 (en) 2021-05-27
IL292926A (en) 2022-07-01
TW202120546A (zh) 2021-06-01
AU2020386669A1 (en) 2022-06-02
CN114728060A (zh) 2022-07-08

Similar Documents

Publication Publication Date Title
CL2008001335A1 (es) Compuestos derivados de pirrolopirimidin-7-ona, antagonistas de los receptores de purina p2x; porceso de preparacion de estos; composicion farmaceutica que los comprende; proceso de preparacion de compuestos intermediarios y usos en el tratamientos del dolor, vejiga hiperactiva, entre otras.
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CL2019000793A1 (es) Moduladores de calpaínas y usos terapéuticos de los mismos.
MX2020003661A (es) Formas de dosificacion de liquidos, metodos de fabricacion y uso.
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
UY37142A (es) Nuevos indazoles 2-sustituidos, procedimientos para su preparación, preparados farmacéuticos que los contienen,así como su uso para la preparación de medicamentos
PA8638801A1 (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
UY36411A (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
CL2019000246A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
BR112015018092A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
CL2019000249A1 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
CL2019001745A1 (es) Conjugados anticuerpo droga para ablacion de celulas madre hematopoyeticas.
UY37456A (es) Inmunoglobulinas y sus usos
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
ECSP21036982A (es) Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso
CL2019000247A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
CO2021005509A2 (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
SV2016005330A (es) Compuestos de 1,3,4-tiadiazol y uso de los mismos para el tratamiento del cã�ncer
BR112018017031A2 (pt) formulações de antagonista de il-6 e usos das mesmas
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
GT201400153A (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
AR121183A1 (es) Métodos de tratamiento de la nefritis lúpica con antagonistas de interleucina-17 (il-17)
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CO2023010562A2 (es) Degradadores irak4 y usos de los mismos